重复静脉输注心脏球源细胞治疗晚期杜氏肌营养不良(HOPE-2):一项多中心、随机、双盲、安慰剂对照的2期试验
HOPE-2试验在美国7个中心纳入26例10岁及以上、中度上肢受损的晚期杜氏肌营养不良男性患者,按1:1随机接受CAP-1002(1.5×10^8个心脏球源细胞)或安慰剂静脉输注,每3个月一次共4次;12个月时肘部中段PUL 1.2评分变化在CAP-1002组优于安慰剂组(百分位差36.2,95%CI 12.7-59.7;评分差2.6分;p=0.014)。3例出现输注相关超敏反应,1例因严重过敏反应终止治疗,无其他重大不良反应及死亡。
要点
- 每3个月静脉输注CAP-1002共4次,12个月时肘部中段PUL 1.2评分变化优于安慰剂(评分差2.6分,p=0.014)。
- 3例出现输注相关超敏反应(无长期后遗症),1例因严重过敏反应终止治疗;无其他重大不良反应及死亡。
- 作者认为CAP-1002在晚期杜氏肌营养不良中似乎安全有效,但需更长期扩展研究确认12个月后的疗效持久性与安全性。
核心结论
- CAP-1002细胞疗法在减少晚期杜氏肌营养不良患者上肢功能恶化方面似乎安全有效。
- CAP-1002组多项心脏功能与结构指标较安慰剂组也有改善。
- 需更长期扩展研究确认CAP-1002治疗杜氏肌营养不良骨骼肌病与心肌病在12个月后的疗效持久性与安全性。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的2期试验,在美国7个中心开展,纳入26例10岁及以上、中度上肢受损的杜氏肌营养不良男性患者。
- 患者按1:1分层区组随机分配,接受CAP-1002(1.5×10^8个心脏球源细胞)或安慰剂静脉输注,每3个月一次,共4次。
- 主要结局为12个月时肘部中段上肢功能表现量表1.2版(PUL 1.2)评分变化,在意向治疗人群中评估;安全性在所有接受研究产品者中评估。
- 2018年3月1日至2020年3月31日入组26例,其中8例随机分至CAP-1002组、12例分至安慰剂组(6例因筛选失败未随机)。
- 试验注册号ClinicalTrials.gov NCT03406780。
主要发现
- 在接受治疗后PUL 1.2评估的患者中(CAP-1002组8例、安慰剂组11例),12个月时肘部中段PUL 1.2评分较基线的平均变化支持CAP-1002优于安慰剂(百分位差36.2,95%CI 12.7-59.7;评分差2.6分;p=0.014)。
- 3例出现输注相关超敏反应、无长期后遗症,其中1例因严重过敏反应终止治疗。
- 未观察到其他重大不良反应,无死亡发生。
- CAP-1002组多项心脏功能与结构指标较安慰剂组改善。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需更长期扩展研究确认CAP-1002在12个月之后的疗效持久性与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiosphere-derived cells (CDCs) ameliorate skeletal and cardiac muscle deterioration in experimental models of Duchenne muscular dystrophy. The HOPE-2 trial examined the safety and efficacy of sequential intravenous infusions of human allogeneic CDCs in late-stage Duchenne muscular dystrophy. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients with Duchenne muscular dystrophy, aged 10 years or older with moderate upper limb impairment, were enrolled at seven centres in the USA. Patients were randomly assigned (1:1) using stratified permuted blocks to receive CAP-1002 (1·5 × 108 CDCs) or placebo intravenously every 3 months for a total of four infusions. Clinicians, caregivers, patients, and clinical operations personnel were fully masked to treatment groups. The primary outcome was the change in mid-level elbow Performance of Upper Limb version 1.2 (PUL 1.2) score at 12 months, assessed in the intention-to-treat population. Safety was assessed in all individuals who received an investigational product. This trial is registered with ClinicalTrials.gov, NCT03406780. FINDINGS: Between March 1, 2018, and March 31, 2020, 26 male patients with Duchenne muscular dystrophy were enrolled, of whom eight were randomly assigned to the CAP-1002 group and 12 to the placebo group (six were not randomised due to screening failure). In patients who had a post-treatment PUL 1.2 assessment (eight in the CAP-1002 group and 11 in the placebo group), the mean 12-month change from baseline in mid-level elbow PUL1.2 favoured CAP-1002 over placebo (percentile difference 36·2, 95% CI 12·7-59·7; difference of 2·6 points; p=0·014). Infusion-related hypersensitivity reactions without long-term sequelae were observed in three patients, with one patient discontinuing therapy due to a severe allergic reaction. No other major adverse reactions were noted, and no deaths occurred. INTERPRETATION: CAP-1002 cell therapy appears to be safe and effective in reducing deterioration of upper limb function in patients with late-stage Duchenne muscular dystrophy. Various measures of cardiac function and structure were also improved in the CAP-1002 group compared with the placebo group. Longer-term extension studies are needed to confirm the therapeutic durability and safety of CAP-1002 beyond 12 months for the treatment of skeletal myopathy and cardiomyopathy in Duchenne muscular dystrophy. FUNDING: Capricor Therapeutics.
引用
- McDonald CM, Marbán E, Hendrix S, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022. PMID: 35279258. doi:10.1016/S0140-6736(22)00012-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。